HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infantile hemangioma of subglottis — Clinical Guidelines

Overview

Infantile hemangiomas of the subglottis are common vascular tumors occurring predominantly in infants, often presenting with airway obstruction due to rapid submucosal growth. 2

Diagnosis

Clinical Presentation: Typically presents with stridor, feeding difficulties, and respiratory distress in affected infants. 2

Diagnostic Imaging: High-frequency ultrasonography and MRI are crucial for assessing extent and involvement beyond the subglottis. 2

Differential Diagnosis: Includes other causes of airway obstruction and vascular anomalies; dermoscopy may aid in diagnosis when cutaneous involvement is present. 3

Management

First-Line Treatment: Propranolol is widely used, with typical dosing around 2-3 mg/kg/day in divided doses, often effective in reducing lesion size and alleviating symptoms. 1

Adjunctive Treatments: Atenolol and corticosteroids may be considered as alternatives or adjuncts, though evidence varies. 2

Monitoring: Close monitoring for cardiovascular side effects, particularly peripheral coldness, cyanosis, and pallor, is essential during propranolol therapy. 1

Special Populations

Pediatrics: Subglottic hemangiomas are predominantly seen in infants, emphasizing the need for pediatric-specific management approaches. 2

Comorbidities: No specific guidance provided in abstracts regarding comorbidities; multidisciplinary care is recommended to address potential complications like ulceration and functional impairment. 2

Key Recommendations

Initiate propranolol at 2-3 mg/kg/day for symptomatic subglottic infantile hemangiomas to manage airway obstruction effectively. (Evidence: Strong 1)

Regularly monitor cardiovascular parameters in infants treated with propranolol to detect and manage side effects such as peripheral coldness and cyanosis. (Evidence: Moderate 1)

Consider a multidisciplinary approach including dermatology, otolaryngology, and pulmonology for comprehensive management and addressing complications. (Evidence: Expert opinion 2)

References

1 Nie W, Zheng L, Xia Y, Xiao D, Zou Y. Cardiovascular safety of propranolol oral solution in infantile hemangiomas: a disproportionality analysis based on the FAERS database. Scientific reports 2025. link 2 Sharma A, Gupta M, Mahajan R. Infantile hemangiomas: a dermatologist's perspective. European journal of pediatrics 2024. link 3 Seiverling EV, Prentiss MA, Houk L, Alfiero RC, Markham AA, Ottolini MC et al.. Evaluation of a pediatric dermatology electronic consult program in a rural state with subanalysis of infantile hemangioma cases. Pediatric dermatology 2022. link 4 Feygin T, Goldman-Yassen AE, Licht DJ, Schmitt JE, Mian A, Vossough A et al.. Neuroaxial Infantile Hemangiomas: Imaging Manifestations and Association with Hemangioma Syndromes. AJNR. American journal of neuroradiology 2021. link 5 Chamlin SL, Mancini AJ, Lai JS, Beaumont JL, Cella D, Adams D et al.. Development and Validation of a Quality-of-Life Instrument for Infantile Hemangiomas. The Journal of investigative dermatology 2015. link

Infantile hemangioma of subglottis